{
    "organizations": [],
    "uuid": "f0d3324770585f483ccc42848966a56d519aff4d",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-trillium-therapeutics-provides-upd/brief-trillium-therapeutics-provides-update-on-its-clinical-programs-idUSASC09VD8",
    "ord_in_thread": 0,
    "title": "BRIEF-Trillium Therapeutics Provides Update On Its Clinical Programs",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "April 10 (Reuters) - Trillium Therapeutics Inc:\n* TRILLIUM THERAPEUTICS PROVIDES UPDATE ON ITS TTI-621 AND TTI-622 CLINICAL PROGRAMS\n* TRILLIUM THERAPEUTICS INC - SUCCESSFUL BROAD SIGNAL-SEEKING EFFORTS IDENTIFY T-CELL LYMPHOMA AS AN INDICATION RESPONSIVE TO TTI-621 THERAPY Source text for Eikon: Further company coverage:\n ",
    "published": "2018-04-10T19:27:00.000+03:00",
    "crawled": "2018-04-11T18:29:51.029+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "april",
        "reuters",
        "trillium",
        "therapeutic",
        "inc",
        "trillium",
        "therapeutic",
        "provides",
        "update",
        "clinical",
        "program",
        "trillium",
        "therapeutic",
        "inc",
        "successful",
        "broad",
        "effort",
        "identify",
        "lymphoma",
        "indication",
        "responsive",
        "therapy",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}